New Market Launch: Tiefenbacher Pharmaceuticals successfully launches the antihistamine Bilastine for a market entry as over-the-counter (OTC) medicine in germany

As the allergy season is starting, we at Tiefenbacher Pharmaceuticals are thrilled to announce that we have successfully prepared the launch of the antihistamine Bilastine for a market entry as Over-the-counter (OTC) medicine in Germany. Bilastine is an innovative anti-allergy medicine for patients suffering from allergic symptoms, such as hay fever and urticaria. It belongs to the non-sedating second-generation antihistamines.

The 20 mg tablets have been developed in TIEFENBACHER GROUP´s own laboratories and will be marketed by our partner, a well-known international pharmaceutical company. With this market entry we enable patients in Germany a better access to an important medicine which is currently the only product of this type available in pharmacies without a prescription needed. Further launches in European markets are planned soon.

AET TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.  

For more information about our finished dosage forms (FDF) including highly potent drugs and healthcare solutions, please contact us at or visit us on

Tiefenbacher new market launch of antihistamine Bilastine in Germany (OTC).
About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at or visit us on: